ストックスクリーナーアプリを入手
14.36
0.28%
-0.04
アフターアワーズ：
14.36
前日終値:
$14.40
開ける：
$14.27
24時間の取引高:
136.55K
Relative Volume:
0.88
時価総額：
$207.09M
収益：
$166.88M
当期純損益:
$-74.18M
株価収益率:
-2.8323
EPS:
-5.07
ネットキャッシュフロー:
$1.14M
1週間 パフォーマンス:
+31.26%
1か月 パフォーマンス:
+34.58%
6か月 パフォーマンス:
+57.98%
1年 パフォーマンス:
-14.83%
1日の値動き範囲:
$14.18
$14.63
1週間の範囲:
$11.60
$14.67
52週間の値動き範囲:
$7.8701
$17.35
Anika Therapeutics Inc Stock (ANIK) Company Profile
名前
Anika Therapeutics Inc
セクター
電話
(781) 457-9000
住所
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.36 | 207.67M | 166.88M | -74.18M | 1.14M | -5.07 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-17 | 開始されました | B. Riley Securities | Buy |
| 2024-11-01 | 繰り返されました | Barrington Research | Outperform |
| 2023-08-14 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 再開されました | Stephens | Equal-Weight |
| 2022-03-09 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 開始されました | Stephens | Overweight |
| 2021-07-16 | 開始されました | UBS | Neutral |
| 2020-12-16 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | アップグレード | Sidoti | Neutral → Buy |
| 2020-01-10 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 開始されました | BWS Financial | Sell |
| 2019-09-24 | 繰り返されました | Barrington Research | Outperform |
| 2019-09-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | アップグレード | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | ダウングレード | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | ダウングレード | Sidoti | Buy → Neutral |
| 2018-07-27 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 繰り返されました | Barrington Research | Outperform |
| 2016-05-09 | アップグレード | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 繰り返されました | Barrington Research | Outperform |
すべてを表示
Anika Therapeutics Inc (ANIK) 最新ニュース
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Anika Therapeutics Is Cheap, But FDA Decisions And OEM Pricing Still Rule - Finimize
Anika Therapeutics debuts Integrity and highlights portfolio at AAOS, Anika Therapeutics asserts - Traders Union
Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70) - TradingView
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal ConferenceSlideshow - Seeking Alpha
ANIK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) sharpens HA strategy with asset sales - Stock Titan
Does Anika Therapeutics, Inc. (ANIK) Have Momentum? - AAII
ANIK | Anika Therapeutics Inc FinancialsIncome Statement - Quiver Quantitative
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results - MarketBeat
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock - MarketBeat
ANIK: Barrington Research Raises Price Target to $17, Maintains 'Outperform' | ANIK Stock News - GuruFocus
Anika Therapeutics showcases Integrity benefits at ACFAS conference - Traders Union
Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating - marketscreener.com
B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating - marketscreener.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIK) 2026-02-27 - Seeking Alpha
Anika Therapeutics Q4 Profit Challenges Narratives Around Ongoing Losses For ANIK Investors - Sahm
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: - GuruFocus
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations - MSN
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Anika Therapeutics Q4 2025 results beat expectations - Investing.com
Anika Therapeutics (ANIK) Reports Consistent Q4 Revenue with Pro - GuruFocus
Anika Therapeutics Q4 Earnings Call Highlights - MarketBeat
Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
ANIKA THERAPEUTICS ($ANIK) Releases Q4 2025 Earnings - Quiver Quantitative
Anika Announces Executive Transition Amid Stable Quarterly Results - TipRanks
Anika: Overview of Fourth Quarter Financial Results - Bitget
Anika: Q4 Earnings Snapshot - marketscreener.com
Anika Therapeutics extends transition agreement with Paul Colleran as EVP, General Counsel - TradingView
Anika (NASDAQ: ANIK) lifts margins as 2025 loss narrows sharply - Stock Titan
BRIEF-Anika Therapeutics Q4 Revenue USD 30.615 Million - TradingView
Osteoarthritis treatments and cost cuts: Anika’s 2026 profit plan - Stock Titan
ANIK Should I Buy - Intellectia AI
Anika Therapeutics cites 40 publications and 16 years of clinical data for Hyalofast cartilage repair - Traders Union
Trading the Move, Not the Narrative: (ANIK) Edition - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference - The Manila Times
Live webcast: Anika CEO speaking at Canaccord musculoskeletal event - Stock Titan
Will Anika Therapeutics Inc. stock recover faster than peersJuly 2025 Levels & Reliable Intraday Trade Plans - mfd.ru
How Anika Therapeutics Inc. stock reacts to Fed rate cuts2025 Year in Review & Free AI Powered Buy and Sell Recommendations - mfd.ru
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 - ChartMill
Published on: 2026-02-13 12:04:47 - baoquankhu1.vn
Anika schedules Feb. 26 call on 2025 financial results - Stock Titan
(ANIK) Volatility Zones as Tactical Triggers - Stock Traders Daily
Published on: 2026-02-11 15:28:04 - mfd.ru
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Lumicell Appoints Cheryl R. Blanchard to board - Medical Buyer
Positive week for Anika Therapeutics, Inc. (NASDAQ:ANIK) institutional investors who lost 41% over the past year - simplywall.st
Anika Therapeutics Inc (ANIK) 財務データ
収益
当期純利益
現金流量
EPS
Anika Therapeutics Inc (ANIK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):